Melanocytic matricoma. Report of a further case with clinicopathological and immunohistochemical findings, differential diagnosis and review of the literature

F. Cartaginese and A. Sidoni
Institute of Pathological Anatomy, Medical School, University of Perugia, Perugia, Italy

Summary. Melanocytic matricoma is a rare recently described lesion. It usually presents as a pigmented, dark-papular, crusted lesion on sun-damaged skin of adult patients. Histopathologically, these lesions are characterized by well-circumscribed nodules composed of matrical and supramatrical cells with clustered shadow cells, and admixed pigmented dendritic melanocytes. It differs from matricomas and pilomatricomas by its lack of calcification, cyst formation, granulomas, and connections to the epidermis and other adnexal structures. The clinical differential diagnosis includes hemangioma, pigmented basal cell carcinoma, and melanoma. Melanocytic matricoma presumably is the representation of an epithelial-melanocytic interaction in the anagen phase of the hair cycle. An extensive search of the medical literature revealed 11 reports of benign melanocytic matricomas and 5 malignant counterparts. We report an additional case of melanocytic matricoma with discussion of clinicopathologic features and differential diagnosis.

Key words: Melanocytic matricoma, Hair follicle, Pilomatricoma, Matricoma, Adnexal tumor

Introduction

In 1999, Carlson and colleagues (Carlson et al., 1999) described two cases of well-circumscribed nodules composed of matrical and supramatrical cells surrounding solitary or clustered “ghost cells” and admixed pigmented dendritic melanocytes. The authors coined the designation “melanocytic matricoma” for these neoplasms.

This peculiar lesion recollects the normal anatomic process that takes place in the healthy bulb of a hair follicle, recapitulating the intimate relationship existing between matrical epithelium and melanocytes in the embryonal hair follicle or in the anagen stage of the hair cycle (Carlson et al., 1999).

Ever since melanocytic matricoma was first described, there has been some discussion about whether there is sufficient clinical and pathologic evidence to support the real existence of this entity (Carlson et al., 2003; Resnik, 2003a,b; Rizzardi and Melato, 2003a,b).

An extensive search of the medical literature revealed that only a few cases of melanocytic matricoma have been reported since the original description, including benign (Carlson et al., 1999; Rizzardi et al., 2002; Williams et al., 2003; Horenstein and Kahn, 2004; Peralta Soler et al., 2007; Islam et al., 2007; Monteagudo et al., 2008) and malignant forms (Sloan et al., 1992; Hardisson et al., 2001; Monteagudo et al., 2003; Jani et al., 2008), and a case in a dog (Saito et al., 2005).

We present a new case of melanocytic matricoma with emphasis on morphological, immunohistochemical and diagnostic features.

Moreover, we have also examined the expression of E-cadherin and β-catenin, proteins that play an important role in the morphogenesis of hair follicles and are crucial in the development of hair follicle-related tumors (Peralta Soler et al., 2007), in order to support the hypothesis that melanocytic matricoma may represent an earlier stage of anagen phase of the hair cycle differentiation.

Material and methods

A 81-year-old male with severely sun-damaged skin presented with an asymptomatic brown-black firm
papule, 15 mm in diameter, on his right forearm. The clinical differential diagnosis included pigmented basal cell carcinoma, thrombosed hemangioma and melanoma. The lesion was surgically excised. No local recurrence was noted at the site of the original excision after a follow-up of 53 months.

The tumor was completely excised. The biopsy specimen was fixed in 10% neutral buffered formalin and embedded in paraffin. Four-micrometer thick sections were stained with hematoxylin-eosin and periodic acid-Schiff.

We performed immunohistochemical studies on 4 µm paraffin sections. The automatized instrument BondMax™ (Vision BioSystems™, Mount Waverley, Australia) and the BondTM polymer refine detection system (Vision BioSystems™, Mount Waverley, Australia) were used to investigate labeling of antibodies to HMB45 (clone HMB45, ready to use, NeoMarkers), melan A (clone A103, rady to use, Novocastra), pancytokeratin (clone AE1/AE3, rady to use, Novocastra) high-molecular-weight cytokeratin (clone 34E12, ready to use, Novocastra), S-100 protein (polyclonal, ready to use, Novocastra), E-cadherin (clone 36B5, ready to use, Novocastra) and ß-catenin (polyclonal, ready to use, NeoMarkers).

For HMB45, melan A, pancytokeratin, high-molecular-weight cytokeratin and E-cadherin, sections were incubated at 25°C for 15 minutes with the respective antibodies and heat-induced epitope retrieval was performed using 0.01M citrate retrieval solution at pH 6.0. For S-100 protein, sections were incubated at 25°C for 15 minutes with the antibody; heat-induced epitope retrieval was not required. For ß-catenin, sections were incubated at 25°C for 20 minutes with the antibody and heat-induced epitope retrieval was performed using 0.01M citrate retrieval solution at pH 6.

Results

Microscopic examination of the surgical specimen revealed a well circumscribed nodule, with asymmetrically distributed black pigmentation, located in the middle and deep dermis (Fig. 1).

The tumor was composed of two cell populations, including an epithelial component and a melanocytic component. The epithelial component was arranged in solid nests and lobules composed of basaloid cells with scant amount of cytoplasm, indistinct cellular borders and prominent nucleoli (reminiscent of matrical and supramatrical cells), which abruptly turned into nucleus-free “shadow cells” with a characteristic ring of keratinized cytoplasm surrounding a lucent center. Basaloid cells displayed mitotic activity and a mild degree of cytological atypia. Admixed with these cells there was a melanocytic component consisting of dendritic melanocytes with abundant melanin pigmentation and scattered aggregates of melanophages (Fig. 2).

Large aggregates of melanin pigment were noted in both the melanocytic and the epithelial components. No granulomatous reaction, calcification, cyst formation, or identifiable connection with the overlying epidermis or adnexal epithelium were observed.

The dermis surrounding the lesion revealed changes of significant sun damage. The epidermis overlying the dermal nodule was flattened and hyperkeratotic, with acanthosis at the periphery.

Immunohistochemically, pancytokeratin and high-molecular-weight cytokeratin (34E12) exhibited positivity for surface epidermis as well as the keratinized “shadow cells”, and, less prominently, the basaloid cells.

Fig. 1. Well delineated and asymmetrically pigmented tumor in the dermis. H&E, original magnification x 12.5.

Fig. 2. Greater magnification shows a biphasic cell population formed by basaloid matrical and supramatrical cells that abruptly turn into nucleus-free “shadow cells” and dendritic melanocytes. H&E, original magnification x 100.
Melan A, S-100 protein and HMB-45 highlighted the morphology of the dendritic melanocytes, which were admixed with the epithelial cells, surrounding them with their process (Fig. 3).

The immunohistochemical studies for β-catenin revealed a cytoplasmatic and nuclear staining in the basaloïd cells and a membranous staining in the intermediate differentiating cells. The fully differentiated “shadow cells” were negative. E-cadherin was at the cell membrane of all cells, with higher expression in keratinocytes than in melanocytes, and was absent in the “shadow cells”. This expression pattern of E-cadherin and β-catenin is identical to the developing hair follicle in anagen phase (Peralta Soler et al., 2007).

Discussion

Melanocytic matricoma was first recognized in 1999 by Carlson and colleagues (Carlson et al., 1999), who reported two cases of a pigmented matrical neoplasm that recapitulates the bulb of the anagen hair follicle, composed of matrical cells and dendritic melanocytes. Subsequently, other case reports have confirmed the uniqueness of this entity (Rizzardi et al., 2002; Williams et al., 2003; Horenstein and Kahn, 2004; Saito et al., 2005; Islam et al., 2007; Peralta Soler et al., 2007; Monteagudo et al., 2008). Including the currently reported case, to our knowledge only twelve cases of melanocytic matricoma have been reported to date (Table 1).

The histogenesis and nomenclature of this tumor is still controversial (Resnik, 2003a,b; Rizzardi and Melato, 2003a,b; Carlson et al., 2003), but it is considered a peculiar entity which differs both clinically and histologically from pilomatrixomas, matricomas and pigmented matricoma variants (Ackerman et al., 1993).

Melanocytic matricoma presents clinically as a small (less than 1 cm) well-circumscribed purple to black papule on sun-damaged skin in the elderly (sixth to seventh decade). Affected sites include the nose, preauricular area, cheek, chest, shoulder and forearm. The clinical differential diagnosis should include pigmented basal cell carcinoma, malignant melanoma and hemangioma (Brenn and McKee, 2005).

Histologically, the appearance of reported cases is quite similar. It presents as a well-circumscribed dermal tumor showing asymmetrical pigmentation. It is arranged in solid nests and lobules composed of basaloïd cells with scant amounts of cytoplasm and prominent nucleoli reminiscent of matrical and supramatrical cells. Cytological atypia, as well as mitotic figures, may be present. Dispersed singly and in small aggregates are “shadow cells” within the tumor, and pigmented dendritic melanocytes are admixed. Surrounding the tumor there is a sclerotic stromal response containing melanophages. The dermis and overlying epidermis reveal changes of significant sun damage including elastosis, epidermal atrophy and actinic keratosis.

The characteristics of melanocytic matricoma, such as small size, well circumscribed borders and lack of

Table 1. Reported cases of melanocytic matricoma.

<table>
<thead>
<tr>
<th>Authors/year</th>
<th>Age</th>
<th>Sex</th>
<th>Size (cm)</th>
<th>Site</th>
<th>Dermatologic history</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlson (1999)</td>
<td>66</td>
<td>M</td>
<td>0.8</td>
<td>Left chest region</td>
<td>BCC</td>
</tr>
<tr>
<td>Carlson (1999)</td>
<td>80</td>
<td>M</td>
<td>0.5</td>
<td>Forearm</td>
<td>Sun damage</td>
</tr>
<tr>
<td>Rizzardi (2002)</td>
<td>62</td>
<td>F</td>
<td>0.6</td>
<td>Nose</td>
<td>Sun damage</td>
</tr>
<tr>
<td>Williams (2003)</td>
<td>78</td>
<td>M</td>
<td>0.4</td>
<td>Left preauricular area</td>
<td>BCC and AK</td>
</tr>
<tr>
<td>Horenstein (2004)</td>
<td>69</td>
<td>M</td>
<td>0.5</td>
<td>Right cheek</td>
<td>Sun damage</td>
</tr>
<tr>
<td>Peralta Soler (2007)</td>
<td>66</td>
<td>F</td>
<td></td>
<td>Right shoulder</td>
<td>BCC</td>
</tr>
<tr>
<td>Islam (2007)</td>
<td>70</td>
<td>M</td>
<td>1.5</td>
<td>Right hand</td>
<td>BCC</td>
</tr>
<tr>
<td>Islam (2007)</td>
<td>82</td>
<td>M</td>
<td>0.5</td>
<td>Right preauricular area</td>
<td>AK, BCC and SCC</td>
</tr>
<tr>
<td>Islam (2007)</td>
<td>76</td>
<td>M</td>
<td></td>
<td>Top part of back</td>
<td>AK</td>
</tr>
<tr>
<td>Monteagudo (2008)</td>
<td>66</td>
<td>M</td>
<td>0.6</td>
<td>Bridge of nose</td>
<td>AK</td>
</tr>
<tr>
<td>Saito (2005)</td>
<td>2</td>
<td>M</td>
<td>2</td>
<td>Tail</td>
<td></td>
</tr>
<tr>
<td>Present case (2010)</td>
<td>81</td>
<td>M</td>
<td>1.5</td>
<td>Right forearm</td>
<td>Sun damage</td>
</tr>
</tbody>
</table>

AK: actinic keratosis; BCC: basal cell carcinoma; SCC: squamous cell carcinoma.
reccurrence, are highly suggestive of a benign nature. In the present case, the long disease-free period observed seems to confirm the benign behaviour of this tumor. The histologic differential diagnoses of melanocytic matricoma include the pigmented variants of pilomatricoma, matrical carcinoma, basal cell carcinoma with matrical differentiation and malignant melanoma (Carlson et al., 1999; Williams et al., 2003).

Melanocytic matricoma is distinctly different from pilomatricoma, both clinically and pathologically. Pilomatricoma occurs in young people as a cystic neoplasm, is firm to the touch, and is located in the deep dermis or subcutaneous tissues; it is often accompanied by calcification of “shadow cells” and granulomatous response to keratinized elements (Carlson et al., 1999). In contrast, melanocytic matricoma presents as a papule in elderly individuals, without connections to the epidermis and other adnexal structures, and calcification and granulomatous reactions are uncommon. Pigmented pilomatricoma does not contain prominent melanocytic hyperplasia, contrasting with the marked proliferation of pigmented dendritic melanocytes in melanocytic matricoma (Zaim, 1971; Cazers et al., 1974; Spitz et al., 1981).

Melanocytic matricoma is morphologically different from so-called matricoma or proliferating pilomatricoma, despite some controversies in this issue (Carlson et al., 2003; Resnik, 2003a,b; Rizzardi and Melato, 2003a,b). According to Ackerman (1993), matricoma is described as having a silhouette composed of multiple small aggregations with cystic, solid and cystic, and solid profiles, positioned throughout the dermis and sometimes just inside the subcutaneous fat. In contrast, melanocytic matricoma is characteristically a single, solid dermal nodule and has a characteristic proliferation of dendritic melanocytes.

Matrical carcinoma with prominent melanocytic hyperplasia has been reported and the possibility of these lesions representing malignant melanocytic matricoma has been raised (Sloan et al., 1992; Hardisson et al., 2001; Monteagudo et al., 2003; Jani et al., 2008). This variant of carcinoma is a poorly defined, multinodular tumor that penetrates deeper layers and contains mitotically active cells and areas of necrosis, with a locally aggressive behaviour (Sloan et al., 1992; Hardisson et al., 2001; Monteagudo et al., 2003; Jani et al., 2008).

Basal cell carcinoma with matrical differentiation is characterized by foci of typical basal cell carcinoma composed of basaloïd nests showing peripheral palisading and stromal retraction artefacts (Del Sordo et al., 2007).

It is known that the bulb of the hair follicles in the anagen phase contains matrical and supramatrical cells, as well as pigmented melanocytes that give hair its colour (Carlson et al., 1999). Because melanocytes are more prominent in the early anagen phase, melanocytic matricoma is suggestive of early-stage follicular differentiation during anagen; this contrasts with pilomatricoma, which is characterized by late-stage differentiation (Carlson et al., 1999; Williams et al., 2003; Horenstein and Kahn, 2004; Peralta Soler et al., 2007; Islam et al., 2007).

Recently, Peralta Soler et al. (2007) have investigated the expression of cadherins and catenins, proteins that play an important role in the morphogenesis of hair follicles and the formation of hair follicle-related tumors, in a case of melanocytic matricoma. Their results have demonstrated that the differential distribution of these proteins in melanocytic matricoma is identical to the developing hair follicle in anagen phase.

In the present case, we have also investigated the distribution of E-cadherin and β-catenin and our results support the previously hypothesized resemblance of this rare tumor to the hair bulb in anagen.

In conclusion, melanocytic matricoma is a distinctive clinical and pathological entity that represents a benign pigmented papule in sun-damaged areas of older individuals, formed by well-circumscribed nodules with groups of “shadow cells” (matrical/supramatrical cells) and prominent pigmented dendritic melanocytes. Dermatologists and dermatopathologists should be aware of this entity and a correct interpretation is extremely important due to its clinical and histopathologic overlap with other malignant lesions.

References
Melanocytic matricoma


Resnik K.S. (2003a). Is melanocytic matricoma a bona fide entity or is it just one type of matricoma? Am. J. Dermatopathol. 25, 166.


Rizzardi C. and Melato M. (2003a). Is melanocytic matricoma a bona fide entity or is it just one type of matricoma?: splitting hairs... in hair matrix tumors! Author’s reply. Am. J. Dermatopathol. 25, 166-167.

Rizzardi C. and Melato M. (2003b). Simply, the point is that pathologists should bear in mind melanocytic matricoma. Am. J. Dermatopathol. 25, 447.


Accepted December 23, 2009